Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Key facts
- Phase
- Phase 4
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07235683
- Record updated
- 17 February 2026
- Original description
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.Read full original descriptionShow less
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients: A Pilot Trial
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.
Inclusion: Recipient of a lung transplant; Has confirmed CMV viremia with a viral load ≥ 1000 IU/mL and will receive or has just started SOC antiviral treatment in the past 72h as per the decision of the treating physician.
Exclusion: Patient receiving cyclosporin, pimozide or ergot alkaloids (due to significant drug interaction with letermovir); Patient receiving or expected to receive CMV immunoglobulin or IVIG during the initial three week treatment phase; Severe hepatic impairment (Child-Pugh Class C); Combined transplant (e.g heart-lung, lung-liver); Known allergy or contraindication to any of the antiviral medications; Renal failure with Creatinine clearance <15 mL/min or requiring dialysis; Participating in another interventional clinical trial; Known antiviral resistance.